


CLAIMS

1. A heterocyclic compound represented by the formula I or a pharmaceutically acceptable salt thereof:



wherein X represents nitrogen atom or CH; R_1 represents halogen atom or hydroxyl; R_2 represents hydrogen atom, hydroxyl or amino; R_3 represents morpholino (which may be substituted with one or two $\text{C}_1\text{-C}_6$ alkyl), pyrrolidinyl (which may be substituted with hydroxy $\text{C}_1\text{-C}_6$ alkyl), NR_6R_7 [R_6 represents $\text{C}_1\text{-C}_6$ alkyl and R_7 represents piperidinyl (which may be substituted with $\text{C}_1\text{-C}_6$ alkyl)], R_4 and R_5 each represent hydrogen atom or $\text{C}_1\text{-C}_6$ alkyl, with the proviso that R_2 is hydrogen atom and R_3 is pyrrolidinyl (which may be substituted with hydroxy $\text{C}_1\text{-C}_6$ alkyl) when R_1 is hydroxyl.

2. The compound according to claim 1 wherein R_1 is chloro.

3. The compound according to claim 1 wherein R₁ is chloro and R₂ is amino.

4. The compound according to claim 1 wherein R₁ is chloro, R₂ is amino, R₃ is dimethylmorpholino, R₄ and R₅ each are hydrogen atom and X is nitrogen atom.

5. The compound according to claim 1 wherein R₁ is chloro and R₂ is hydroxyl.

6. The compound according to claim 1 wherein R₁ is chloro, R₂ is hydroxyl, R₃ is morpholino, R₄ and R₅ each are hydrogen atom and X is nitrogen atom.

7. The compound according to claim 1 wherein R₁ is hydroxyl, R₂ is hydrogen atom and R₃ is pyrrolidinyl (which may be substituted with hydroxymethyl).

8. The compound according to claim 1 wherein the compound represented by the formula I is 2-(2-difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(2-hydroxymethylpyrrolidin-1-yl)-6-morpholinopyrimidine, 2-(6-amino-4-chloro-2-difluoromethylbenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholino-1,3,5-triazine, 2-(6-amino-4-chloro-2-difluoromethylbenzimidazol-1-yl)-4-(2-

hydroxymethylpyrrolidin-1-yl)-6-morpholino-1,3,5-triazine, 2-(6-amino-4-chloro-2-difluoromethylbenzimidazol-1-yl)-4-[methyl(1-methylpiperidin-4-yl)amino]-6-morpholino-1,3,5-triazine, 2-(2-difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(2-hydroxymethylpyrrolidin-1-yl)-6-morpholino-1,3,5-triazine or 2-(4-chloro-2-difluoromethyl-5-hydroxybenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine.

9. The compound according to claim 1 wherein the compound represented by the formula I is 2-(2-difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(2-hydroxymethylpyrrolidin-1-yl)-6-morpholino-1,3,5-triazine.

10. An antitumor agent comprising at least one of compounds as claimed in any of claims 1 to 9 as effective component.

11. A pharmaceutical composition including the compound as claimed in any of claims 1 to 9 as an antitumor active component together with pharmaceutically acceptable diluent or carrier.